Supplementary Search: Ongoing Studies Given the growing interest in repurposing GLP-1 medications for substance use disorders (Yammine et al., 2025), several ongoing and planned study protocols are implementing neuroimaging tasks to rigorously examine the mechanism of GLP-1 in reducing brain reactivity to drug-related cues (Freet et al., 2024

Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network (2022) Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program, Diabetes Care (2022) What causes obesity & overweight?, Eunice Kennedy Shriver National Institute of Child Health and Human Development (2021) Compounding and the FDA: Questions and Answers, Food and Drug Administration (2024) Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes, Reviews in Endocrine and Metabolic Disorders (2022) FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) Thinking of using a compounding pharmacy
Your gp should investigate
Youll be paired with a clinician who can find the right medication for you and prescribe it if needed
The localized injection strategy aims to maximize effects in specific muscles while minimizing systemic exposure